Figure 2.

Neutralization of variant spike pseudotyped viruses by convalescent sera, antibodies elicited by RNA, and adenoviral vector vaccines

(A) Neutralization of pseudotyped viruses with D614G, Beta, Delta, Delta+N501S, Mu, and C.1.2 (-T716I) variant spikes by convalescent serum samples from eight donors was tested. The serum was collected at 32–57 days after infection. Each dot represents the IC₅₀ for a single donor. Neutralization titers of variants were compared with that of D614G.

(B and C) Neutralizing titers of serum samples from BNT162b2-vaccinated individuals (n = 9), mRNA-1273-vaccinated donors (n = 8), and Ad26.COV2.S-vaccinated individuals (n = 10) were measured. Sera were collected at 90, 80, and 82 days on average after the last immunization. IC₅₀ of neutralization of virus from individual donors is shown. Significance was based on two-sided testing.

(D) Neutralization titers of viruses with single point mutations by antibodies elicited by BNT162b2. Neutralizing titers of serum samples from BNT162b2-vaccinated individuals (n = 5). Sera were collected 7 days after second immunization. Each dot represents the IC₅₀ for a single donor.

(E) Neutralizing titers of serum samples from BNT162b2-vaccinated individuals with (n = 5) or without previous SARS-CoV-2 infection (n = 12) was measured. The neutralization IC₅₀ of virus from individual donors is shown. The sera were collected 7 days after the second immunization. The sera were collected prior to February 2021. Thus, the individuals were not infected with Delta and would have been infected with D614G, Alpha, or Iota variant. Significance was based on two-sided testing. ^∗p ≤ 0.05, ^∗∗p ≤ 0.01, ^∗∗∗p ≤ 0.001, ^∗∗∗∗p ≤ 0.0001. The experiment was done twice with similar results.